Company ProfilePremium

Photonike Capital SA

Company Profile Analysis

Ticker: MLPHO.PA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Photonike Capital SA - Company showcase

Year Founded & Workforce

2008

Photonike Capital SA logo

Photonike Capital SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Photonike Capital SA Overview

Photonike Capital SA is a Brussels-domiciled micro-cap holding company that has repositioned itself three times in sixteen years. It started as a photovoltaic developer, became an industrial turnaround investor, and now pursues a Belgian reinsurance and insurance strategy. It describes itself as a provider of "bespoke risk protection solutions" across industrial, financial and technological risk, and as a manager of turnaround processes. Its stated offering covers credit enhancement, market hedging and alternative-finance structures.

Its main live strategic project is obtaining a non-life reinsurance or insurance licence from the National Bank of Belgium (NBB), first applied for in 2020–2021 and still pending in 2026. In practice it is a closely held vehicle: about 80% of shares are held by two holding companies (Homepad SA and FFVentriglia Investment & Finance Ltd). Revenue is sporadic and contract-driven, with about EUR 1.76 million in FY2024 and almost none in earlier years. The shares trade thinly and far below the book values the company has asserted.


Company's own description. Photonike states that it is "a service provider of bespoke risk protection solutions (industrial, financial and technological) as well as a management company of industrial and financial turnaround processes" (Euronext/Cofisem company profile, updated 27 Jan 2025). Aggregator profiles derived from company material add that it "offers tailor made solutions for credit enhancement, market hedging, and alternative finance purposes" (Yahoo Finance; FMP).

Independent characterisation. On the evidence available, Photonike operates as a personal holding and deal vehicle rather than an operating company with a recurring business. Its activity has been organised around a small number of large, episodic projects:

  1. Industrial turnarounds in Italy (2013 to late 2010s). It took control of Sandretto, the historic injection-moulding-machine maker at Pont Canavese near Turin, and invested in GBM Holding SpA. It financed these investments with bespoke quasi-equity instruments ("Photonike Special Swap 2017", "Special Convertible 2024", "Special Swap 2020") totalling about EUR 8.18 million, which were later converted to equity (2021 special board report). The Sandretto investment ended badly: trade press reported the company going into liquidation, and Photonike wrote down its Sandretto receivables in the FY2025 accounts (press release, 4 Jul 2026).

  2. Insurance and reinsurance platform (2019 to present). In 2019 it announced an entry into European life insurance. It took a stake in Nucleus Life AG, a Liechtenstein life insurer, approved by the FMA Liechtenstein in July 2021, placed representatives on its board, and in January 2024 announced control of the holding vehicle Nucleus Holding II ScSP (Luxembourg). In 2020–2021 it applied to the NBB for a non-life reinsurance licence. The 2021–2025 business plan was built around this licence, but it has not been granted as of mid-2026. A 2022 attempt to buy an Italian non-life insurer (referred to in releases as the "Argo"/"AGA Italy" deal) has no publicly confirmed completion.

  3. Contract-based risk-protection services (2024). In August 2024 it announced a contract worth EUR 1.7 million. This aligns closely with reported FY2024 revenue of EUR 1.76 million, but the link is an inference; the contract counterparty and scope are not disclosed.

  4. Technology adjacency (2023 to present). It announced the "release of AESG-AI algorithms" in March 2023. In 2025 it invested about EUR 100,000 in an Italian AI developer that will build its risk-assessment software (press release, 30 Jun 2026).

Business and revenue model.

Strategy

Stated strategy themes (from company releases and the 2021–2025 plan):

  1. Become a licensed Belgian non-life (re)insurer in credit, suretyship, financial-loss and legal-expenses classes. The 30 Jun 2026 release says the insurance team "has refined the licensing application criteria and appointed official liaison representatives with NBB".

  2. Build an insurance group around Nucleus Life AG and Nucleus Holding II ScSP.

  3. Apply AI to risk assessment, through the AESG-AI algorithms (2023) and outsourced risk-assessment software development (2025–2026).

  4. Exit legacy Italian industrial exposure, including writing down Sandretto receivables (FY2025).

Initiatives in the last 24 months (Oct 2024 to Oct 2026):

ESG commitments: none disclosed. Cost programmes: none disclosed.

Medium-term targets. The only published financial targets are the Business & Development Plan 2021–2025 projections for the planned reinsurer:

Source: photonike.com, Business and Development Plan 2021–2025 (Retail Investors Release, 18 Mar 2021). Plan years were not mapped to calendar years in the extract.

Assessment. Because the licence was never obtained, none of these projections materialised. Actual net results over the plan period were losses of EUR 387–450k (FY2021–FY2022) and a profit of EUR 575k (FY2024). The plan should be regarded as superseded. No current guidance exists.

Products & Services

Photonike publishes no product catalogue with specifications or pricing. The offerings below are those named in company material.

Product Portfolio

OfferingDescriptionTarget customerYearPricingSource

Bespoke risk-protection solutions

Tailor-made protection against industrial, financial and technological risks

Corporates

Ongoing

—

Euronext/Cofisem profile

Credit enhancement

Structures that improve the credit standing of a client's obligations

Corporates, borrowers

Ongoing

—

Yahoo/FMP profile

Market hedging

Hedging solutions against market risk

Corporates

Ongoing

—

Same

Alternative finance

Non-bank financing structures, historically including proprietary "Special Swap" and "Special Convertible" instruments (2013–2014)

Investee companies, investors

2013–

—

Same; 2021 Special Board Report

Turnaround management

Management of industrial and financial restructurings (Sandretto precedent)

Distressed industrial companies

2013–

—

Euronext/Cofisem profile

Planned non-life reinsurance

Lines of business in the 2021–2025 plan include Class 14 Credit (insolvency, export credit, instalment credit, mortgages, agricultural credit), Class 15 Suretyship (direct, indirect), Class 16 Miscellaneous financial loss (employment risk, insufficient income, bad weather, loss of benefits, loss of market value, loss of rent/revenue, other financial loss) and Class 17 Legal expenses

Insurers, corporates

Planned since 2020; licence pending

Premium-based (projected only)

Business & Development Plan 2021–2025

Life insurance (through Nucleus Life AG)

Life-insurance products. A new product catalogue was launched in Feb 2024.

Retail and HNW clients

2024 catalogue

—

Release, 26 Feb 2024

AESG-AI algorithms

Proprietary algorithms related to ESG/risk assessment

Internal / clients

Mar 2023

—

Release, 24 Mar 2023

Risk-assessment software (in development)

AI-based risk-assessment tool being built by an Italian AI company in which Photonike invested about EUR 100k

Internal underwriting

2025–2026

Not applicable

Release, 30 Jun 2026

Captive insurance (exploratory)

Market commentary on captive insurance in France suggests interest in captive structures

Corporates

Sep 2023

—

Release, 20 Sep 2023

“—” = not publicly disclosed.

Financial Narrative

Income statement

Source notes:

  • FY2021–FY2022 operating and net income: Cofisem/Euronext, with year alignment inferred. The prior years in the same series are FY2020 (operating -15, net -52) and FY2019 (operating +20, net -11).

  • FY2024 revenue, gross profit, other expenses and earnings: Simply Wall St, which shows EUR 1.8M revenue, EUR 0 cost of revenue, EUR 1.2M other expenses and EUR 576.4k earnings. Yahoo shows revenue of EUR 1.76M and net income of EUR 576.39k.

  • The company's AGM release (20 Feb 2026) gives FY2024 net profit as EUR 575,070. The discrepancy of about EUR 1.3k against aggregators is noted; the company figure is used.

  • FY2024 EPS of 0.0054 is from Simply Wall St and is consistent with 575,070 / 105.8M shares. Yahoo displays diluted EPS of -0.0000, an apparent data error.

  • The Cofisem table shows a "Net sales 34" value whose year cannot be reliably assigned, so it is excluded.

  • Dividends: none paid in any year reviewed (Boursorama: last dividend EUR 0.00).

Margins and growth

FY2024 net margin is computed as 575 / 1760 = 32.7%. Yahoo reports 32.77%. A 5-year revenue CAGR is not computable because revenue in earlier years was nil or undisclosed.

Balance sheet

Disclosed capital-structure data points outside the table:

  • The June 2021 Special Board Report proposed converting EUR 8,181,569 of "debt for shares to be issued" into equity at a nominal value of EUR 0.695 per share. This would take share capital to EUR 12,248,572.09, and then, after incorporating share premium, to EUR 73,523,618.91, with the stated aim of meeting reinsurer minimum paid-up capital thresholds. Further reserve and liability incorporations were executed in 2022–2023.

  • The company stated on 19 Dec 2020 that its FY2019 audit report confirmed a book value of EUR 6.65–7.00 per share. At about 105.8M shares that implies equity of roughly EUR 700M or more, which is irreconcilable with a EUR 11M market value and EUR 0.6M of annual profit. The asset values backing it, largely investments and receivables tied to Italian industrial positions, were written down at least in part in FY2025 (Sandretto receivables, 4 Jul 2026).

  • Simply Wall St rates the balance sheet as "mediocre" with "4 risks" flagged.

Cash flow

The FY2025 strategic investment is the approximately EUR 100k investment in an Italian AI developer (30 Jun 2026 release). No buyback programmes have been disclosed.

Ratios

None of these ratios can be computed from public data.

Commentary

Trend. The audited and aggregated record shows a company with no meaningful revenue from FY2019 to FY2022. It ran small operating losses of tens of thousands of euros, but net losses were materially larger (EUR -450k in FY2021 and EUR -387k in FY2022 on the inferred alignment). That gap points to financial charges, write-downs or investment-related losses below the operating line.

Inflection. FY2024 is the only year with substantial revenue: about EUR 1.76M at a 100% gross margin, producing net profit of EUR 575,070. Management described this as having "returned the company to profitability in 2024" (30 Jun 2026 release). The timing and size match the EUR 1.7M contract announced on 20 Aug 2024. The revenue therefore looks like a single-contract event, not evidence of a recurring earnings base.

Deterioration risk for FY2025. The 4 Jul 2026 release on the write-down of Sandretto receivables, followed by a "Financial Statements 2025 update" on 22 Sep 2026, strongly suggests FY2025 includes a material impairment. Neither the size of the write-down nor the FY2025 result was retrievable, so both are left blank rather than estimated.

Reporting discipline. Accounts have been chronically late:

  • FY2022 accounts were approved on 2 Jan 2024.

  • FY2023 accounts were delayed "for technical reasons" (17 Dec 2024) and approved on 22 Jul 2025, about 19 months after year-end.

  • FY2024 accounts were approved on 20 Feb 2026, about 14 months after year-end.

This lag is itself a material governance and credit signal.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRelationshipActivityStatus / source

Photonike Capital SA

Belgium

Listed parent

Risk-protection services, holding, reinsurance licence applicant

Active

Nucleus Holding II ScSP

Luxembourg

Control announced 8 Jan 2024

Insurance holding vehicle

Ownership % not disclosed

Nucleus Life AG

Liechtenstein

Investee; FMA approval Jul 2021; Ventriglia board chair from Oct 2022

Life insurance. FY2023 net profit CHF 596,897 (release 18 Apr 2024).

Stake % not disclosed

TriCap Assurance

—

Described as "subsidiary" in an Aug 2020 release

Insurance

Status not disclosed

Italian AI developer (unnamed)

Italy

About EUR 100k investment in 2025

Risk-assessment software

Name not disclosed

Sandretto SpA

Italy

Former subsidiary

Injection-moulding machines

In liquidation per trade press; receivables written down FY2025

GBM Holding SpA

Italy

Former investee

—

Status not disclosed

GlobaQ Industries Corporation

USA

Planned subsidiary at IPO (2010)

Solar-panel plant

No evidence it became operational

“—” = not publicly disclosed.

Segment Overview

SegmentFY2024

Total company revenue (EUR K)

1,760

Risk-protection / structuring services (EUR K)

1,760

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR K)

———1,760—

Gross profit (EUR K)

———1,760—

Other operating expenses (EUR K)

———1,200—

Operating income (EUR K)

-38-35———

Net income (EUR K)

-450-387—575—

EPS basic (EUR)

———0.0054—

Dividend per share (EUR)

00000

Margin Analysis (%)

MetricFY2024

Gross margin (%)

100

Net margin (%)

32.7

Key Financials

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (EUR K)

00000

Share buybacks (EUR K)

00000

Strategic investments (EUR K)

————100

Region Overview

RegionFY2024

Total (EUR K)

1,760

Share Price and Market Valuation

MetricFY2024FY2026

Observed share price (EUR)

0.130.10

Market capitalisation (EUR Mn)

13.7511

Shares outstanding (M)

105.8—

Share Price & Returns

PeriodReturnSource / note

1-year

-40.17%

Zonebourse snapshot (date of snapshot not confirmed)

3-year

-63.16%

Same

3-year (alternate snapshot)

-92.23%

Zonebourse CH (different date)

Valuation Multiples

MultiplePhotonikePeer note

P/E (FY2024)

About 18.4x

Simply Wall St/Yahoo show "–"

EV/Sales

Not computable (net debt unknown)

Not applicable

P/Sales

About 6.0x

Computed

EV/EBITDA

Not computable

Not applicable

P/B

Not computable on audited equity. On the company's 2020 claim of EUR 6.65–7.00 BVPS it would be about 0.015x, an implausible figure that indicates the claim should not be relied on.

Not applicable

Item

Status

—

Analyst consensus

None; no sell-side coverage

—

Dividend history / policy

No dividends paid; no policy disclosed

—

Buybacks

None authorised or disclosed

—

Credit ratings (Moody's/S&P/Fitch)

None. Only a Dun & Bradstreet commercial rating of 5A2 (Feb 2024).

—

Debt maturity profile

Not disclosed. Legacy instruments carried maturities of 2017, 2020 and 2024; these were proposed for conversion to equity in 2021.

—

Daily price limits (Boursorama, Aug 2026)

Down limit EUR 0.0990, up limit EUR 0.1210

—

Liquidity

Zero volume on the last observed session; "capital échangé" 0.00%

—

Analyst Conclusions

Management guidance. No current financial guidance has been given. The 2021–2025 business plan has expired unachieved. The only forward-looking statements are qualitative: pursuing the NBB licence and developing AI risk-assessment software (30 Jun 2026).

Consensus expectations. None; there is no analyst coverage.

Bull case

  1. Licence optionality. The NBB process is ongoing, with refined criteria and appointed liaisons. Authorisation would turn a EUR 11M shell into a regulated carrier with the plan's modelled earnings power (Year-5 net profit EUR 10.96M), a large multiple of today's market value.

  2. Demonstrated profitability. FY2024 showed the model can generate high-margin contract income (EUR 1.76M revenue, 32.7% net margin). Two or three similar contracts a year would support a sub-10x P/E.

  3. Legacy clean-up. Writing down Sandretto receivables in FY2025 could mark the end of the Italian industrial overhang and simplify the equity story.

Bear case

  1. Execution record. A solar plan (2010), the Sandretto turnaround, the Fiera di Roma bid, the Italian insurer acquisition (2022) and the Euronext Growth uplisting (2023) all failed or went unconsummated. The reinsurer licence has been pending for more than five years.

  2. Transparency and governance. Accounts are approved 14–19 months late, one draft was unaudited, the auditor is unidentified, Euronext has issued a compliance notice, and asserted book values cannot be reconciled with reality.

  3. Earnings quality. The FY2024 profit appears tied to a single EUR 1.7M contract, and the FY2025 accounts include impairments. Recurring earnings power is unproven.

Key catalysts and monitorables (next 12 months)

  • Final approved and audited FY2025 accounts, including the size of the Sandretto write-down and the resulting equity.

  • Any NBB decision on the (re)insurance licence.

  • Clarity on who manages the company after the March 2025 withdrawal.

  • Outcome of the Euronext trading-compliance matter.

  • New contract announcements comparable to August 2024.

  • Disclosure of the Nucleus Holding II ScSP stake and consolidated insurance economics.

  • Liquidity: whether trading resumes on a regular basis.

Analyst verdict

Photonike Capital SA is best understood as a closely controlled, sparsely disclosed holding vehicle whose public equity is a small appendage to a long-running ambition: becoming a licensed Belgian non-life reinsurer. Sixteen years after its 2010 debut as a solar developer, the company has cycled through renewable energy, Italian industrial turnarounds and insurance investments. Each phase was announced with considerable ambition, and few produced verifiable shareholder value.

The FY2024 return to profit, with net income of EUR 575,070, is real and documented by an AGM-approved account. However, it appears to rest on one EUR 1.7 million contract and cannot yet be extrapolated. The FY2025 accounts, now in draft and already "updated", carry a write-down of legacy Sandretto receivables. That is a reminder that the asset values underpinning past claims of multi-euro book value per share were not sound.

The investment case reduces to a binary option on regulatory authorisation, wrapped in significant governance discount:

  • control concentrated at about 80%;

  • a combined chair and CEO, alongside an ambiguous statement that management withdrew in March 2025;

  • accounts approved more than a year late, one draft unaudited and the current auditor unidentified;

  • an exchange compliance notice.

Liquidity is minimal, with days passing without trades, so even a correct thesis may be hard to monetise.

On the available evidence, Photonike does not meet basic institutional standards for investability: audited timely accounts, transparent capital, an independent board and tradable liquidity. A market value of about EUR 11 million represents roughly 18 times a single year's contract-driven profit, with no visibility on cash, debt or equity. That valuation is not cheap for the risk borne.

The stock should be regarded as speculative and unsuitable for institutional portfolios. It warrants reconsideration only if three things happen: audited FY2025 accounts clarify equity and liquidity, the NBB grants a licence, and governance reforms (an independent board, timely reporting and a named auditor) are put in place.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureBackground / notes

Fausto M. Ventriglia

Chairman & CEO (per Cofisem/Euronext, Jan 2025; FMP; Simply Wall St)

Since at least 2013–2015. Shareholder of about 25% in the mid-2010s per La Notizia.

Sole administrator of Sandretto SpA (2014). Chairman of the Nucleus Life AG board from Oct 2022. Age and education not disclosed.

Claudio Marati

Shareholder (0.82%); historically 16.6% holder

—

Board role not confirmed

Claude Chapelnot

Investor contact

—

Listed as Euronext company contact

Luciano Minerva, Roberto Moretti

Historical shareholders (16.6% each, mid-2010s)

—

Per La Notizia

“—” = not publicly disclosed.

Governance Overview

IndicatorAssessment

Chair/CEO separation

No: combined role (Ventriglia)

Committees

None disclosed

Audit status

FY2023 draft published "Not Audited". Auditor for FY2022 onward not identified.

Reporting timeliness

Poor: accounts approved 12–19 months after year-end

Exchange scrutiny

Euronext notice on "trading compliance of shares" (15 Sep 2025).

Market communication

Company issued a "warning for fake news" about itself on an investment forum (7 Feb 2024)

Uplisting

Euronext Growth move announced and then abandoned within 4 weeks (Oct 2023)

Major Shareholders

HolderStake (%)Type

Homepad SA

68.14

Holding company (beneficial owner not disclosed)

FFVentriglia Investment & Finance Ltd

12.26

Holding company, apparently linked to the Chairman/CEO by name

Claudio Marati

0.82

Individual

Fausto M. Ventriglia (direct)

0.70

Chairman & CEO

Free float (residual)

about 18.08

Computed

Competitive Landscape

Competitors by Segment

AreaCompetitorsRelative positioning

Credit and suretyship (re)insurance

Allianz Trade, Atradius, Coface, Credendo (Belgium), Swiss Re, Munich Re, SCOR

Photonike is unlicensed and has no premium base; these are global incumbents with billions in premiums

Bespoke risk transfer / structured solutions

Swiss Re Corporate Solutions, Munich Re (Risk Solutions), AXA XL, Marsh (captives)

Photonike has no ratings, no capital disclosure and no track record

Captive management (France/Belgium)

Marsh Captive Solutions, Aon Captive & Insurance Management

Exploratory only

Liechtenstein life insurance (Nucleus Life AG)

Liechtenstein Life, Prisma Life, Swiss Life (Liechtenstein)

Nucleus Life is small (FY2023 profit CHF 0.6M)

Listed small-cap holding/turnaround vehicles

Various Euronext Access/Growth holdings

Comparable in scale only

Peer Comparison FY2024

MetricPhotonike FY2024Coface FY2024SCOR FY2024

Revenue

EUR 1.76M

About EUR 1.8bn

About EUR 20bn

Net margin

32.7%

About 13%

Not meaningful (net loss in 2024)

Growth

Not meaningful

Low single digit

—

Company Snapshot

$1.9M

Revenue

2008

Founded

Brussels, Belgium

Headquarters

SWOT Analysis

Strengths

  • Returned to profit in FY2024 with net income of EUR 575,070 (AGM release, 20 Feb 2026).
  • 100% gross margin on FY2024 revenue of EUR 1.76M, consistent with an asset-light services model (Simply Wall St).
  • A presence in licensed insurance through Nucleus Life AG, which made a CHF 596,897 profit in FY2023, and control of Nucleus Holding II ScSP (releases of 18 Apr 2024 and 8 Jan 2024).
  • Has completed the first phase of NBB reinsurer assessment (10 Dec 2021) and appointed NBB liaison representatives (30 Jun 2026).
  • Large legacy liabilities were converted to equity (EUR 8.18M debt-equity swap per the 2021 board report), reducing contractual debt.
  • D&B rating improved to 5A2 in February 2024.

Weaknesses

  • Chronic reporting delays: FY2023 accounts approved about 19 months after year-end, FY2024 about 14 months.
  • FY2023 draft accounts published unaudited (13 Aug 2024). Auditor for FY2022 onward not identified.
  • Revenue concentration: FY2024 revenue of about EUR 1.76M closely matches a single EUR 1.7M contract (20 Aug 2024).
  • Net losses of EUR 387–450k in FY2021–FY2022 despite minimal operations (Cofisem).
  • Failed Sandretto turnaround, ending in liquidation and an FY2025 write-down of receivables.
  • Concentrated control: about 80% held by Homepad SA and FFVentriglia, with a free float of about 18%.

Opportunities

  • An NBB licence would unlock the credit, suretyship and financial-loss lines modelled in the 2021–2025 plan (Year-5 projected net profit EUR 10.96M).
  • AI-enabled underwriting through the EUR 100k Italian AI investment (2025).
  • Growth at Nucleus Life AG after its new product catalogue (Feb 2024).
  • A renewed uplisting to Euronext Growth (attempted in Oct 2023) could improve liquidity.
  • Demand for captive and alternative risk transfer (company's Sep 2023 focus on the French captive market).
  • Repeating bespoke contracts like the 2024 EUR 1.7M deal.

Threats

  • Licence denial or further delay. The application has been pending since 2020–2021 with no grant by Oct 2026.
  • Exchange compliance action, given the Euronext trading-compliance notice of 15 Sep 2025.
  • Further impairments of legacy assets, following the Sandretto write-down in FY2025.
  • Reputational damage from adverse Italian press coverage (La Notizia) and forum controversies (fake-news warning, Feb 2024).
  • Share illiquidity and price erosion: -40% over one year and -63% over three years per a Zonebourse snapshot; another snapshot shows -92% over three years.
  • Management continuity uncertainty after the stated withdrawal of management in March 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Jan 2024Takes control of Nucleus Holding II ScSP Euronext feedInsurance consolidation
12 Jan 2024Nucleus Life AG estimates FY2023 profit Euronext feedInvestee performance
18 Jan 2024Nucleus Life AG and Nucleus Group information Euronext feedDisclosure
5 Feb 2024D&B rating raised from 5A3 to 5A2 Euronext feedModest credit signal
7 Feb 2024Warning about fake news on an investment web forum Euronext feedCommunication or reputational issue
26 Feb 2024Nucleus Life AG closes 2023 in profit and launches new product catalogue Euronext feedInvestee
18 Apr 2024Nucleus Life AG FY2023 net profit CHF 596,897 Euronext feedInvestee result
29 Apr 2024Nucleus Life AG AGM approves FY2023 Euronext feedInvestee
13 Aug 2024Unaudited draft FY2023 accounts published Euronext feedAudit gap
20 Aug 2024Contract worth EUR 1.7M closed Euronext feedDrives FY2024 revenue (inferred)
17 Dec 2024FY2023 approval delayed "for technical reasons" Euronext feedReporting delay
16 Jun 2025FY2023 draft completed for approval Euronext feedReporting
2 Jul 2025AGM convened for FY2023; draft FY2024 accounts published Euronext feedReporting
22 Jul 2025Shareholders approve FY2023 accounts Euronext feedAbout 19 months after year-end
11 Sep 2025FY2024 accounts "to be approved" Euronext feedReporting
15 Sep 2025Euronext notice about trading compliance of shares Euronext feedExchange-compliance concern
20 Jan 2026AGM convened for FY2024; annual accounts published Euronext feedReporting
20 Feb 2026AGM approves FY2024 with net profit of EUR 575,070 Euronext feedFirst profit in the reviewed period
21 Feb 2026AGM minutes published Euronext feedGovernance
30 Jun 2026Draft FY2025 accounts published Euronext feed–
30 Jun 2026Business development update: NBB licensing work, management withdrawal (Mar 2025), EUR 100k AI investment Euronext feedStrategy
4 Jul 2026Information on write-down of Sandretto receivables in FY2025 accounts Euronext feedImpairment of legacy assets
7 Aug 2026Last recorded trade at EUR 0.100 BoursoramaIlliquidity
21 Sep 2026Business Development Update Euronext feed–
22 Sep 2026"Financial Statements 2025 update" Euronext feedPossible revision of FY2025 draft

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total company revenue was EUR 1.8 Mn in FY2024.
Photonike Capital SA — Revenue by Segment
Series (EUR Mn)FY2024
Total company revenue1.8
Risk-protection / structuring services1.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Euronext Live: company press-release feed for Photonike Capital (2019–2026); company information page (Cofisem key figures and shareholders, updated 27 Jan 2025); IPO showcase (22 Apr 2010); company news of 30 Jun 2026.
  2. Photonike Capital SA: Business and Development Plan 2021–2025, Retail Investors Release (photonike.com); Special Board Report on capital increases (dated 24 Jun 2021, filed 22 Jun 2023).
  3. Simply Wall St (MLPHO, FY2024 key details); Yahoo Finance (MLPHO.PA, May 2026); Financial Modeling Prep (profile; valuation dated 22 Apr 2024); Morningstar AU (profile); Boursorama (quote as of 7 Aug 2026); Zonebourse / MarketScreener (news and performance snapshots); dividend.watch; Disfold; PitchBook profile.
  4. MacPlas (Sandretto relaunch, 2014; Sandretto liquidation); La Notizia Giornale (Fiera di Roma bid and company background).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.